GLP-1 Franchise Leadership and the Next Wave of Cardiometabolic Growth

Eli Lilly and Company is a global pharmaceutical manufacturer headquartered in Indianapolis, Indiana, with a portfolio spanning cardiometabolic health, oncology, immunology, and neuroscience. The company generates revenue primarily through the sale of branded prescription medicines, with the largest and fastest-growing contribution coming from its incretin franchise.

How the company makes money:

• Incretin medicines: Tirzepatide, marketed as Mounjaro (type 2 diabetes) and Zepbound (obesity and obstructive sleep apnea), represents the dominant revenue growth driver. These are chronic therapies dosed weekly via autoinjector, generating recurring per-patient revenue.
• Diabetes portfolio: Legacy insulins (Humalog, Basaglar) and SGLT2 inhibitors provide a stable, if slower-growing, base.
• Oncology: Verzenio (abemaciclib) for breast cancer is the largest oncology contributor, with a growing label across adjuvant and metastatic settings.
• Immunology: Taltz (ixekizumab) for psoriasis, psoriatic arthritis, and axial spondyloarthritis.
• Neuroscience: Includes migraine (Emgality) and Alzheimer's (donanemab/Kisunla), the latter a longer-duration call option given the complexity of diagnosis and infusion logistics.

Customers: The primary customers are wholesale pharmaceutical distributors in the U.S. (which then supply retail pharmacies, PBMs, and health systems), national health systems and distributors in ex-U.S. markets, and a growing direct-to-consumer cash-pay channel for obesity medicines.

Scale: With a market capitalization of $1060.6B, 891.74M shares outstanding, and trailing EPS of $29.81, Lilly is the largest pharmaceutical company globally by market value. The public float of 888.95M shares represents approximately 99.7% of shares outstanding, indicating minimal insider or strategic ownership concentration.

Near-term (12–24 months):

• Capacity conversion: The primary near-term driver is the pace at which Lilly brings new API and fill-finish capacity online. Each incremental capacity tranche converts directly into revenue because demand currently exceeds supply in the obesity indication.
• Label expansion: Zepbound's obstructive sleep apnea indication and ongoing cardiovascular outcomes data expand the reimbursable population and strengthen payer negotiations.
• International rollout: Mounjaro launches in additional ex-U.S. markets, particularly in Asia and Latin America, where diabetes prevalence is high and pricing is negotiated but volumes are large.
• Oral GLP-1 readouts: Orforglipron Phase 3 data are the single most important near-term catalyst, as a positive readout would validate a much larger addressable market.

Medium-term (3–5 years):

• Primary care penetration: If oral incretins are approved, the treatment paradigm shifts from specialist-driven to primary-care-driven, potentially multiplying the patient pool.
• Combination therapies: Amylin/incretin combinations and next-generation molecules could drive incremental efficacy and extend the franchise's competitive moat.
• Alzheimer's contribution: Donanemab, if adoption accelerates with improved diagnostic infrastructure (blood-based biomarkers, PET), could become a multibillion-dollar contributor, though timelines are uncertain.
• Policy and pricing: Medicare negotiation, IRA provisions, and potential international reference pricing represent the largest medium-term headwinds to realized net price.

Note: FY2023 and FY2024 figures are historical; FY2025E–FY2027E are analyst estimates and should be treated as illustrative projections rather than company guidance.

The financial trajectory is driven almost entirely by incretin volume growth and operating leverage. Revenue growth of 30%+ in the current period reflects both volume expansion and a favorable mix shift toward higher-priced obesity medicines, while gross margin expansion reflects manufacturing scale efficiencies as new capacity comes online. R&D as a percentage of revenue is declining not because absolute R&D is falling — it is rising from $9.3B to an estimated $15.0B — but because the revenue base is growing faster, which is the classic signature of a franchise hitting its commercial inflection. Trailing EPS of $29.81 already exceeds the FY2027E estimate shown above, implying either that consensus forward estimates lag actual run-rate earnings or that the trailing figure includes items not representative of the ongoing base; investors should reconcile the trailing figure against the most recent quarterly filings before extrapolating.

Market size: The global incretin market (GLP-1 and dual-agonist therapies for diabetes and obesity) is estimated in the range of $50–60B currently, with consensus projections of $100–150B by the early 2030s depending on oral entrant success and payer coverage expansion. The broader obesity treatment market, if defined to include all pharmacotherapies, could exceed $200B at peak penetration. Lilly and Novo Nordisk together account for the overwhelming majority of current incretin revenue.

Competitive positioning: Lilly's key differentiator is the dual GIP/GLP-1 mechanism of tirzepatide, which has demonstrated superior weight loss versus semaglutide in head-to-head trials. This efficacy advantage supports premium positioning and share gains, though Novo Nordisk's manufacturing scale and established commercial infrastructure make it a formidable competitor. The competitive dynamic is currently capacity-constrained rather than share-constrained — both companies sell everything they can produce — which means the near-term battle is about manufacturing execution, not marketing.

Named comparable companies:

DCF discussion: A discounted cash flow framework for Lilly is unusually sensitive to two assumptions: the terminal growth rate of the incretin franchise and the probability-weighted contribution of the oral GLP-1 pipeline. Using a WACC in the 7–8% range (justified by the 0.50 beta and investment-grade credit profile) and a terminal growth rate of 3.5–4.5%, a DCF that assumes incretin revenue peaks in the late 2030s and declines modestly thereafter would support a valuation broadly in line with the current $1194.09 share price, assuming mid-single-digit terminal growth. Upside to the DCF comes primarily from a higher oral GLP-1 penetration assumption; downside comes from faster-than-expected net price erosion or a competitive efficacy surprise from Novo Nordisk or Amgen.

Comparable company multiples:

LLY multiples derived from the live data provided ($1194.09 price, $29.81 EPS, $1060.6B market cap). Comparable company figures are approximate and for illustrative comparison only.

Lilly's premium multiple versus peers reflects its superior growth rate and the market's confidence in the durability of the incretin franchise. The spread between LLY's ~40x trailing P/E and Merck's ~15x or Pfizer's ~12x is roughly proportional to the growth differential, suggesting the premium is fundamentally justified rather than purely momentum-driven — though it also means there is limited multiple-expansion cushion if growth decelerates.

• Manufacturing and supply chain execution: The entire near-term growth thesis rests on Lilly's ability to bring new API and fill-finish capacity online on schedule. Delays in facility qualification, regulatory inspection, or cold-chain logistics would directly cap revenue regardless of demand.

• Competitive efficacy and pricing pressure: Novo Nordisk's next-generation candidates, Amgen's MariTide, and a wave of Chinese and Western oral GLP-1 entrants could erode Lilly's efficacy leadership and force price concessions. A single head-to-head trial loss in a major indication would materially reset the franchise's economics.

• Payer and policy intervention: Medicare drug price negotiation, IRA provisions, international reference pricing, and state-level pricing legislation represent a structural threat to realized net price. The obesity indication is particularly exposed because payers have historically restricted coverage, and broad coverage expansion could come with corresponding price concessions.

• Pipeline failure risk: Orforglipron, donanemab, and the amylin combination programs are all binary in nature. A Phase 3 failure in the oral GLP-1 program would remove a substantial portion of the medium-term growth optionality embedded in the current valuation.

• Valuation and positioning risk: At ~40x trailing earnings and with a $1060.6B market cap, LLY is priced for near-flawless execution. Any deceleration in revenue growth, margin compression, or a shift in institutional positioning (short interest is currently only 0.89% of float, leaving limited room for a short squeeze but also indicating crowded long positioning) could produce outsized multiple compression.